Registry for babies with retinopathy of prematurity
Part of Eyes & vision, Genetic & congenital clinical trials.
This study is a European registry that collects medical information (stored electronically) about babies who have retinopathy of prematurity (ROP) severe enough to need treatment. It may help doctors understand outcomes and improve care by tracking real-world results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby has retinopathy of prematurity (ROP) that requires treatment based on local guidelines
- A parent or legal guardian can give consent for the study’s electronic storage of your baby’s personal medical data
- The study needs permission to document and store your baby’s information for registry use
- If consent is not given, your baby cannot be included
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at newborn eye exams and genetic information to better understand why some premature infants develop a serious vision problem called ROP. You may be invited because your baby needs routine eye screening or is being moved for specialized eye care.
This study looks at eye structure in children who were in an earlier premature-baby eye study and are now around 4.5–5 years old. It may help researchers better understand how eye disease in prematurity develops and how to monitor it.
This study looks at how often premature babies weighing more than 1500 grams or born at 33 weeks or later get a serious eye condition called ROP (retinopathy of prematurity). It aims to find out what puts these babies at risk and what happens to them, helping doctors improve screening guidelines.
This study uses pictures to map the tiny blood vessels in an infant’s retina (the back of the eye). It may help researchers better understand how eye blood vessel growth happens in premature babies who need screening for ROP (retinopathy of prematurity).
This study collects information on how the medicine Eylea is given to preterm babies with retinopathy of prematurity (an eye problem in premature infants) using a special dosing device. The goal is to see how the treatment works in everyday hospital care.
This study looks at how often low oxygen levels happen in premature babies when they get eye injections for a serious eye condition. The goal is to understand the risks and make the procedure safer.
Hear when a new Retinopathy of Prematurity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.